


AMENDMENT TO THE CLAIMS

1. (Previously Presented) An acylated 1,2,3,4-tetrahydronaphthyl amine according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein

R^1 and R^4 are independently of each other chosen from:

H; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and C_2 - C_{10} -alkynyl, the substituents of which are chosen from F, OH, C_1 - C_8 -alkoxy, $(C_1$ - C_8 -alkyl)mercapto, CN, $COOR^6$, $CONR^7R^8$, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; R^9CO ; $CONR^{10}OR^{11}$; $COOR^{12}$; CF_3 ; halogens; pseudohalogens; $NR^{13}R^{14}$; OR^{15} ; $S(O)_mR^{16}$; $SO_2NR^{17}R^{18}$; and NO_2 ;

R_2 and R_3 are independently of each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C_1 - C_{10} -alkoxy; phenoxy; $S(O)_mR^{19}$; CF_3 ; CN; NO_2 ; $(C_1$ - C_{10} -alkyl)amino; di(C_1 - C_{10} -alkyl)amino; $(C_1$ - C_6 -alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl- SO_2 -O-, the substituents of which are chosen from halogens, pseudohalogens, CH_3 and methoxy; $(C_1$ - C_6 -alkyl) SO_2 -O-; unsubstituted and at least monosubstituted $(C_1$ - C_6 -alkyl)CO, the substituents of which are chosen

from F, di(C₁-C₃-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C₁-C₃-alkyl, halogens and methoxy;

A is chosen from CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is chosen from CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

R⁵ is a group Hetar which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH₂; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, NH₂, (C₁-C₈-alkyl)amino, and di(C₁-C₈-alkyl)amino; C₃-C₃-alkandiyl; phenyl; heteroaryl; aryl-substituted C₁-C₄-alkyl; heteroaryl-substituted C₁-C₄-alkyl; CF₃; NO₂; OH; phenoxy; benzyloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino; benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶SO₂NH-; R²⁷SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is chosen from:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents chosen from F, C₁-C₈-alkoxy, and di(C₁-C₃-alkyl)amino; aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents, chosen from F, C₁-C₈-alkoxy, di(C₁-C₃-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from : C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens,

pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃, and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S; aryl is phenyl, naphth-1-yl or naphth-2-yl;

m is 0, 1 or 2;

with the proviso that, where R¹, R², R³ and R⁴ are hydrogen or one of the substituents, R¹ R², R³

or R^4 is C_1 - C_6 -alkoxy, R^5 is not unsubstituted pyridyl or unsubstituted or substituted 4-oxoquinoliny;

where one of the groups R^1 and R^2 is hydroxy and the other groups of R^1 , R^2 , R^3 , and R^4 are hydrogen, R^5 is not unsubstituted pyridyl; and

where groups A, B, and C are each CH_2 , R^5 is not 5-nitrofuryl.

2. (Previously Presented) The acylated 1,2,3,4-tetrahydronaphthyl amine in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (I)

R^1 is chosen from H; C_1 - C_4 -alkyl; C_1 - C_4 -alkoxy; CF_3 ; halogens; pseudohalogens; (C_1 - C_4 -alkyl)- $S(O)_m$ -; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 , and wherein heteroaryl is chosen from 5- and 6-membered heterocycles containing one or more heteroatoms chosen from N, O, and S;

R^2 and R^3 are independently of each other chosen from :

H; halogens; pseudohalogens; and C_1 - C_3 -alkyl;

R^4 independently has the same meaning as R^1 ;

A is chosen from CH_2 and $CHOH$;

B and C are independently of each other chosen from CH_2 and $CH-CH_3$;

R^5 is a group Heter which can be unsubstituted or carry one or more substituents chosen from: halogens; CN ; NH_2 ; unsubstituted and at least monosubstituted C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_2 - C_8 -alkynyl, C_1 - C_8 -alkoxy, (C_1 - C_8 -alkyl)amino, and di(C_1 - C_8 -alkyl)amino, the substituents of which are chosen from F, C_1 - C_6 -alkoxy, phenoxy, (C_1 - C_6 -alkyl)mercapto, NH_2 , (C_1 - C_6 -alkyl)amino, and di(C_1 - C_6 -alkyl)amino; C_3 - C_5 -alkandiyl; phenyl; heteroaryl; phenyl-substituted C_1 - C_2 -alkyl; heteroaryl-substituted C_1 - C_2 -alkyl; CF_3 ; OH; phenoxy; benzyloxy; (C_1 - C_6 -

alkyl)COO; S(O)_m(C₁-C₆)-alkyl; S(O)_m-phenyl; S(O)_m-heteroaryl; SH; phenylamino; benzylamino; (C₁-C₆-alkyl)-CONH-; (C₁-C₆-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₆-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COO(C₁-C₆-alkyl); -CONH₂; -CONH(C₁-C₆-alkyl); -CON(di(C₁-C₆-alkyl)); CNH(NH₂); -SO₂NH₂; -SO₂NH(C₁-C₆-alkyl); -SO₂NH(phenyl); -SO₂N(di(C₁-C₆-alkyl)); (C₁-C₆-alkyl)SO₂NH-; (C₁-C₆-alkyl)SO₂N(C₁-C₆-alkyl)-; phenyl-SO₂NH-; phenyl-SO₂N(C₁-C₆-alkyl)-; heteroaryl-SO₂NH-; heteroaryl-SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo, and CF₃, and wherein said heterocycles can optionally be condensed to said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S; and

m is 0 or 2.

3. (Previously Presented) The acylated 1,2,3,4-tetrabydronaphthyl amine in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (I)
- R¹ is H, halogen or C₁-C₄-alkyl;

R^2 and R^3 are each H;

R^4 independently has the same meaning as R^1 ;

A is CH_2 ;

R^5 is a group Heter which can be unsubstituted or carry one or more substituents chosen from:

halogens; CN; NH_2 ; unsubstituted and at least monosubstituted C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 -

C_6 -alkynyl, C_1 - C_3 -alkoxy, $(\text{C}_1$ - C_4 -alkyl)amino, and $\text{di}(\text{C}_1$ - C_4 -alkyl)amino, the substituents of

which are chosen from F, C_1 - C_3 -alkoxy, $(\text{C}_1$ - C_3 -alkyl)mercapto, and NH_2 ; C_3 - C_5 -alkandiyl;

phenyl; heteroaryl; phenyl-substituted C_1 - C_2 -alkyl; heteroaryl-substituted C_1 - C_2 -alkyl; CF_3 ; OH;

$(\text{C}_1$ - C_4 -alkyl)COO; $\text{S}(\text{O})_m(\text{C}_1$ - C_4 -alkyl); $(\text{C}_1$ - C_4 -alkyl)-CONH-; $(\text{C}_1$ - C_4 -alkyl)-CON $(\text{C}_1$ - C_4 -alkyl)-;

$(\text{C}_1$ - C_4 -alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3 -CO; $-\text{OCH}_2\text{O}-$;

$-\text{OCF}_2\text{O}-$; $-\text{OCH}_2\text{CH}_2\text{O}-$; $-\text{CH}_2\text{CH}_2\text{O}-$; $\text{COO}(\text{C}_1$ - C_6 -alkyl); $-\text{CONH}_2$; $-\text{CONH}(\text{C}_1$ - C_4 -alkyl); -

$\text{CON}(\text{di}(\text{C}_1$ - C_4 -alkyl)); $\text{CNH}(\text{NH}_2)$; $-\text{SO}_2\text{NH}_2$; $-\text{SO}_2\text{NH}(\text{C}_1$ - C_4 -alkyl); $-\text{SO}_2\text{NH}(\text{phenyl})$; -

$\text{SO}_2\text{N}(\text{di}(\text{C}_1$ - C_4 -alkyl)); $(\text{C}_1$ - C_4 -alkyl) $\text{SO}_2\text{NH}-$; $(\text{C}_1$ - C_4 -alkyl) $\text{SO}_2\text{N}(\text{C}_1$ - C_4 -alkyl)-

and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1

to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more

substituents chosen from halogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy, OH, oxo and CF_3 , and wherein

said heterocycles can optionally be condensed to said group Heter; and wherein all heteroaryl,

phenyl-, heteroaryl-containing and phenyl-containing groups, which are optionally present in said

substituents of said group Heter, can be substituted by one or more substituents chosen from

halogens, pseudohalogens, C_1 - C_3 -alkyl, OH, C_1 - C_3 -alkoxy, and CF_3 ;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or

three heteroatoms chosen from N, O, and S;

the group Heter is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one,

two or three heteroatoms chosen from N, O, and S; and

m is 0 or 2.

4. (Previously Presented) The acylated 1,2,3,4-tetrahydronaphthyl amine in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof according to claim 1, wherein in the formula (I)

R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A and B are each CH₂;


C is CH₂ or CH-CH₃;

R⁵ is a group Heter which can be unsubstituted or carry one or more substituents chosen from: F; Cl; Br; C₁-C₃-alkyl; C₁-C₃-alkoxymethyl; 2-amino-3,3,3-trifluoro-propyl-; CF₃; C₃-C₃-alkandyl; phenyl; heteroaryl; benzyl; heteroaryl-methyl; OH; C₁-C₃-alkoxy; phenoxy; trifluoromethoxy; 2,2,2-trifluoroethoxy; (C₁-C₄-alkyl)COO; (C₁-C₃-alkyl)mercapto; phenylmercapto; (C₁-C₃-alkyl)sulfonyl; phenylsulfonyl; NH₂; (C₁-C₄-alkyl)amino; di(C₁-C₄-alkyl)amino; (C₁-C₃-alkyl)-CONH-; (C₁-C₃-alkyl)-SO₂NH-; (C₁-C₃-alkyl)-CO; phenyl-CO; -OCH₂O-, -OCF₂O-, -CH₂CH₂O-, COO(C₁-C₄-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl); -CON(di(C₁-C₄-alkyl)); CN; -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂N(di(C₁-C₄-alkyl)); pyrrolidinyl; piperidinyl; morpholinyl; and thiomorpholinyl; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl - containing groups, which are optionally present in said substituents of said group Heter, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzthiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl;

the group Hetar is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl.

5. (Previously Presented) An acylated 1,2,3,4-tetrahydronaphthyl amine according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;


A and B are each CH₂;

C is CH₂ or CH-CH₃;

R⁵ is chosen from: benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzoimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzoimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-

dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, 2-methyl-3H-benzoimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl, 2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methyl-isoxazole-4-yl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethylsulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-methyl-thiazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 5-thiophen-2-yl-pyrid-3-yl, 2-methyl-4-trifluoromethyl-thiazol-5-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

6. (Previously Presented) A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering said mammal a physiologically active amount of a compound according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R^1 and R^4 are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and C_2 - C_{10} -alkynyl, the substituents of which are chosen from F, OH, C_1 - C_8 -alkoxy, (C_1 - C_8 -alkyl)mercapto, CN, $COOR^6$, $CONR^7R^8$, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; R^9CO ; $CONR^{10}R^{11}$; $COOR^{12}$; CF_3 ; halogens; pseudohalogens; $NR^{13}R^{14}$; OR^{15} ; $S(O)_mR^{16}$; $SO_2NR^{17}R^{18}$; and NO_2 ;

R^2 and R^3 are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C_1 - C_{10} -alkoxy; phenoxy; $S(O)_mR^{19}$; CF_3 ; CN; NO_2 ; (C_1 - C_{10} -alkyl)amino; di(C_1 - C_{10} -alkyl)amino; (C_1 - C_6 -alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl- SO_2 -O-, the substituents of which are chosen from halogens, pseudohalogens, CH_3 and methoxy; (C_1 - C_6 -alkyl) SO_2 -O-; unsubstituted and at least monosubstituted (C_1 - C_6 -alkyl)CO, the substituents of which are chosen from F, di(C_1 - C_3 -alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C_1 - C_3 -alkyl, halogens and methoxy;

A is chosen from CH_2 , CHOH and CH -(C_1 - C_3 -alkyl);

B is chosen from CH_2 and $\text{CH}-(\text{C}_1-\text{C}_3\text{-alkyl})$;

C independently has the same meaning as B;

R^5 is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH_2 ; unsubstituted and at least monosubstituted C_1-C_{10} -alkyl, C_2-C_{10} -alkenyl, C_2-C_{10} -alkynyl, C_1-C_{10} -alkoxy, $(\text{C}_1-\text{C}_{10}$ -alkyl)amino, and $\text{di}(\text{C}_1-\text{C}_{10}$ -alkyl)amino, the substituents of which are chosen from F, OH, C_1-C_8 -alkoxy, aryloxy, $(\text{C}_1-\text{C}_8\text{-alkyl})$ mercapto, NH_2 , $(\text{C}_1-\text{C}_8\text{-alkyl})$ amino, and $\text{di}(\text{C}_1-\text{C}_8\text{-alkyl})$ amino; C_3-C_5 -alkandiyl; phenyl; heteroaryl; aryl- substituted C_1-C_4 -alkyl; heteroaryl -substituted C_1-C_4 -alkyl; CF_3 ; NO_2 ; OH; phenoxy; benzyloxy; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{COO}$; $\text{S}(\text{O})_m\text{R}^{20}$; SH; phenylamino; benzylamino; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CONH-}$; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; phenyl- CONH- ; phenyl- $\text{CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; heteroaryl- CONH- ; heteroaryl- $\text{CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CO}$; phenyl- CO ; heteroaryl- CO ; $\text{CF}_3\text{-CO}$; $-\text{OCH}_2\text{O-}$; $-\text{OCF}_2\text{O-}$; $-\text{OCH}_2\text{CH}_2\text{O-}$; $-\text{CH}_2\text{CH}_2\text{O-}$; COOR^{21} ; $\text{CONR}^{22}\text{R}^{23}$; $\text{CNH}(\text{NH}_2)$; $\text{SO}_2\text{NR}^{24}\text{R}^{25}$; $\text{R}^{26}\text{SO}_2\text{NH-}$; $\text{R}^{27}\text{SO}_2\text{N}(\text{C}_1-\text{C}_6\text{-alkyl})\text{-}$; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C_1-C_3 -alkyl, C_1-C_3 -alkoxy, OH, oxo and CF_3 , and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C_1-C_3 -alkyl, OH, C_1-C_3 -alkoxy, and CF_3 ;

R^6 is chosen from:

H; C_1-C_{10} -alkyl, which can be substituted by one or more substituents chosen from F, C_1-C_8 -alkoxy, and $\text{di}(\text{C}_1-\text{C}_8\text{-alkyl})$ amino; aryl- $(\text{C}_1-\text{C}_4\text{-alkyl})$ and heteroaryl- $(\text{C}_1-\text{C}_4\text{-alkyl})$, which can be

substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₈-alkoxy, di(C₁-C₈-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2.

7. (Previously Presented) The method according to claim 6, wherein in the formula (I)
- R^1 is chosen from: H; C_1 - C_4 -alkyl; C_1 - C_4 -alkoxy; CF_3 ; halogens; pseudohalogens; (C_1 - C_4 -alkyl)- $S(O)_m$ -; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 , and wherein heteroaryl is chosen from 5- and 6-membered heterocycles containing one or more heteroatoms chosen from N, O, and S;
- R^2 and R^3 are independently from each other chosen from: H; halogens; pseudohalogens; and C_1 - C_3 -alkyl;
- R^4 independently has the same meaning as R^1 ;
- A is chosen from CH_2 and $CHOH$;
- B and C are independently from each other chosen from CH_2 and $CH-CH_3$;
- R^5 is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; CN; NH_2 ; unsubstituted and at least monosubstituted C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_2 - C_8 -alkynyl, C_1 - C_8 -alkoxy, (C_1 - C_8 -alkyl)amino, and di(C_1 - C_8 -alkyl)amino, the substituents of which are chosen from F, C_1 - C_6 -alkoxy, phenoxy, (C_1 - C_6 -alkyl)mercapto, NH_2 , (C_1 - C_6 -alkyl)amino, and di(C_1 - C_6 -alkyl)amino; C_3 - C_5 -alkandiy; phenyl; heteroaryl; phenyl-substituted C_1 - C_2 -alkyl; heteroaryl-substituted C_1 - C_2 -alkyl; CF_3 ; OH; phenoxy; benzyloxy; (C_1 - C_6 -alkyl)COO; $S(O)_m$ (C_1 - C_6 -alkyl); $S(O)_m$ -phenyl; $S(O)_m$ -heteroaryl; SH; phenylamino; benzylamino; (C_1 - C_6 -alkyl)-CONH-; (C_1 - C_6 -alkyl)-CON(C_1 - C_4 -alkyl)-; phenyl-CONH-; phenyl-CON(C_1 - C_4 -alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C_1 - C_4 -alkyl)-; (C_1 - C_6 -alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3 -CO; $-OCH_2O-$; $-OCF_2O-$; $-OCH_2CH_2O-$; $-CH_2CH_2O-$; $COO(C_1-C_6-alkyl)$; $-CONH_2$; $-CONH(C_1-C_6-alkyl)$; $-CON(di(C_1-C_6-alkyl))$; $CNH(NH_2)$; $-SO_2NH_2$; $-SO_2NH(C_1-C_6-alkyl)$; $-SO_2NH(phenyl)$; $-SO_2N(di(C_1-C_6-alkyl))$; (C_1 - C_6 -alkyl) SO_2NH- ; (C_1 - C_6 -alkyl) $SO_2N(C_1-C_6-alkyl)-$; phenyl- SO_2NH- ; phenyl- $SO_2N(C_1-C_6-alkyl)-$; heteroaryl- SO_2NH- ; heteroaryl- $SO_2N(C_1-C_6-alkyl)-$; and saturated and at least monounsaturated

aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0 or 2.

8. (Previously Presented) The method according to claim 6, wherein in the formula (I)

R¹ is H, halogen, or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A is CH₂;

R⁵ is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; CN; NH₂; unsubstituted and at least monosubstituted C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₃-alkoxy, (C₁-C₄-alkyl)amino, and di(C₁-C₄-alkyl)amino, the substituents of which are chosen from F, C₁-C₃-alkoxy, (C₁-C₃-alkyl)mercapto, and NH₂; C₃-C₅-alkandiyl; phenyl; heteroaryl; phenyl-substituted C₁-C₂-alkyl; heteroaryl-substituted C₁-C₂-alkyl; CF₃; OH; (C₁-C₄-alkyl)COO; S(O)_m(C₁-C₄)-alkyl; (C₁-C₄-alkyl)-CONH-;

(C₁-C₄-alkyl)-CON(C₁-C₄-alkyl)-; (C₁-C₄-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COO(C₁-C₆-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl); -CON(di(C₁-C₄-alkyl)); CNH(NH₂); -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂NH(phenyl); -SO₂N(di(C₁-C₄-alkyl)); (C₁-C₄-alkyl)SO₂NH-; (C₁-C₄-alkyl)SO₂N(C₁-C₄-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said phenyl or said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said phenyl or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃; heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms chosen from N, O, and S; the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms chosen from N, O, and S; and m is 0 or 2.

9. (Previously Presented) The method according to claim 6, wherein in the formula (I)

R¹ is H, halogen, or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A and B are each CH₂;

C is CH₂ or CH-CH₃;

R⁵ is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: F; Cl; Br; C₁-C₃-alkyl; C₁-C₃-alkoxymethyl; 2-amino-3,3,3-trifluoro-

propyl-; CF₃; C₃-C₅-alkandyl; phenyl; heteroaryl; benzyl; heteroaryl-methyl; OH; C₁-C₃-alkoxy; phenoxy; trifluoromethoxy; 2,2,2-trifluoroethoxy; (C₁-C₄-alkyl)COO; (C₁-C₃-alkyl)mercapto; phenylmercapto; (C₁-C₃-alkyl)sulfonyl; phenylsulfonyl; NH₂; (C₁-C₄-alkyl)amino; di(C₁-C₄-alkyl)amino; (C₁-C₃-alkyl)-CONH-; (C₁-C₃-alkyl)-SO₂NH-; (C₁-C₃-alkyl)-CO; phenyl-CO; -OCH₂O-; -OCF₂O-; -CH₂CH₂O-; COO(C₁-C₄-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl); -CON(di(C₁-C₄-alkyl)); CN; -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂N(di(C₁-C₄-alkyl)); pyrrolidinyl; piperidinyl; morpholinyl; and thiomorpholinyl; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said phenyl or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃; heteroaryl is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl; the group Hetar is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl.

10. (Previously Presented) The method according to claim 6, wherein in the formula (I)

R¹ is H, halogen or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A and B are each CH₂;


C is CH₂ or CH-CH₃;

R⁵ is chosen from: 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-(C₁-C₃-alkoxy)-phenyl, 4-trifluoromethoxyphenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 3,4-dimethylphenyl, 2,4-dimethylphenyl, 4-chloro-2-methylphenyl, 2-hydroxy-4-methylphenyl, 2-hydroxy-4-ethoxyphenyl, 2-methoxy-4-methylphenyl, 4-phenoxyphenyl, 3-fluoro-4-methylphenyl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzimidazole-5-yl, 2-methyl-3H-benzimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl, 2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3-dimethylamino-4-methyl-phenyl, 3-dimethylamino-phenyl, 3H-benzimidazole-5-yl, 1H-benzimidazole-5-yl, 3-methanesulfonylamino-2-methyl-phenyl, 3-methanesulfonylamino-phenyl, 3-methyl-isoxazole-4-yl, 3-morpholin-4-yl-phenyl, 3-piperidin-1-yl-phenyl, 3-pyrrolidin-1-yl-phenyl, 4-(2,2,2-trifluoro-ethoxy)-phenyl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethyl sulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-

chloro-3-methanesulfonylamino-phenyl, 4-chloro-3-sulfamoyl-phenyl, 4-methyl-3-methylamino-phenyl, 4-methyl-thiazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 5-thiophen-2-yl-pyrid-3-yl, 2-methyl-4-trifluoromethyl-thiazol-5-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methanesulfonyl-2-methyl-phenyl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

11. (Original) The method according to claim 6, wherein the mammal is a human.
- 12-17. (Cancelled)
18. (Original) A pharmaceutical preparation comprising an effective dose of at least one compound of the formula (I) as defined in claim I in any of its stereoisomeric forms or a mixture thereof in any ratio and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
19. (Original) A pharmaceutical preparation according to claim 18, which pharmaceutical preparation is in the form of a pill, tablet, lacquered tablet, sugar-coated tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant or rod.

20. (Previously Presented) A method for synthesis of a compound according to claim 1, which method comprises coupling reaction of respective 1,2,3,4-tetrahydronaphthyl amine with a respective acid or acid chloride in the presence of an appropriate base and/or an appropriate coupling agent, optionally followed by a functionalization of the thus-obtained compound.
21. (Currently Amended) ~~The A method according to claim 12 of treating a mammal suffering from hypertension~~ wherein the hypertension is chosen from essential hypertension, pulmonary hypertension, secondary hypertension, and renovascular hypertension, which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I), in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R¹ and R⁴ are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl and C₂-C₁₀-alkynyl,

the substituents of which are chosen from F, OH, C₁-C₈-alkoxy, (C₁-C₈-alkyl)mercapto, CN,

COOR⁶, CONR⁷R⁸, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the

substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and

CF₃; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which

are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; R⁹CO:

CONR¹⁰R¹¹; COOR¹²; CF₃; halogens; pseudohalogens; NR¹³R¹⁴; OR¹⁵; S(O)_mR¹⁶; SO₂NR¹⁷R¹⁸;

and NO₂;

R² and R³ are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C₁-C₁₀-alkoxy; phenoxy; S(O)_mR¹⁹; CF₃; CN; NO₂; (C₁-C₁₀-alkyl)amino; di(C₁-C₁₀-alkyl)amino; (C₁-C₈-alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl-SO₂-O-, the substituents of which are chosen from halogens, pseudohalogens, CH₃ and methoxy; (C₁-C₆-alkyl)SO₂-O-; unsubstituted and at least monosubstituted (C₁-C₆-alkyl)CO, the substituents of which are chosen from F, di(C₁-C₃-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C₁-C₃-alkyl, halogens and methoxy;

A is chosen from CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is chosen from CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

R⁵ is a group Ar or a group Heter both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH₂; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, NH₂, (C₁-C₈-alkyl)amino, and di(C₁-C₈-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; aryl-substituted C₁-C₄-alkyl; heteroaryl-substituted C₁-C₄-alkyl; CF₃; NO₂; OH; phenoxy; benzyloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino; benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶SO₂NH-; R²⁷SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles

containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is chosen from:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, and di(C₁-C₃-alkyl)amino; aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₃-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, di(C₁-C₃-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₃-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;


aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2;

wherein the physiologically active amount of the compound according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof stimulates the expression of endothelial NO-synthase in the mammal.

22. (Currently Amended) The A method according to claim 12 of treating a mammal suffering from diabetes complications wherein the diabetes complications are chosen from nephropathy and retinopathy-- , which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I) , in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R¹ and R⁴ are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl and C₂-C₁₀-alkynyl,

the substituents of which are chosen from F, OH, C₁-C₃-alkoxy, (C₁-C₃-alkyl)mercapto, CN,

COOR⁶, CONR⁷R⁸, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the

substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; R⁹CO; CONR¹⁰R¹¹; COOR¹²; CF₃; halogens; pseudohalogens; NR¹³R¹⁴; OR¹⁵; S(O)_mR¹⁶; SO₂NR¹⁷R¹⁸, and NO₂;

R² and R³ are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C₁-C₁₀-alkoxy; phenoxy; S(O)_nR¹⁹; CF₃; CN; NO₂; (C₁-C₁₀-alkyl)amino; di(C₁-C₁₀-alkyl)amino; (C₁-C₆-alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl-SO₂-O-, the substituents of which are chosen from halogens, pseudohalogens, CH₃ and methoxy; (C₁-C₆-alkyl)SO₂-O-; unsubstituted and at least monosubstituted (C₁-C₆-alkyl)CO, the substituents of which are chosen from F, di(C₁-C₃-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C₁-C₃-alkyl, halogens and methoxy;

A is chosen from CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is chosen from CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

R⁵ is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH₂; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are chosen from F, OH, C₁-C₃-alkoxy, aryloxy, (C₁-C₃-alkyl)mercapto, NH₂, (C₁-C₃-alkyl)amino, and di(C₁-C₃-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; aryl-substituted C₁-C₄-alkyl; heteroaryl-substituted C₁-C₄-alkyl; CF₃; NO₂; OH; phenoxy; benzyloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino;

benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₃-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₃-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₃-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶SO₂NH-; R²⁷SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is chosen from:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, and di(C₁-C₃-alkyl)amino; aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, di(C₁-C₃-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least

monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁶;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₃-alkoxy, aryloxy, (C₁-C₃-alkyl)mercapto, (C₁-C₃-alkyl)amino and di(C₁-C₃-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁵;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;


aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2;

wherein the physiologically active amount of the compound according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof stimulates the expression of endothelial NO-synthase in the mammal.

23. (Currently Amended) The A method according to claim 12, which ~~method lowers~~ of lowering cardiovascular risk of postmenopausal women and mammals taking contraceptives- , which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I) , in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R¹ and R⁴ are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl and C₂-C₁₀-alkynyl, the substituents of which are chosen from F, OH, C₁-C₈-alkoxy, (C₁-C₈-alkyl)mercapto, CN, COOR⁶, CONR⁷R⁸, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃; R⁹CO; CONR¹⁰R¹¹; COOR¹²; CF₃; halogens; pseudohalogens; NR¹³R¹⁴; OR¹⁵; S(O)_mR₁₆; SO₂NR¹⁷R¹⁸; and NO₂;

R² and R³ are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C₁-C₁₀-alkoxy; phenoxy; S(O)_mR¹⁹; CF₃; CN; NO₂; (C₁-C₁₀-alkyl)amino; di(C₁-C₁₀-alkyl)amino; (C₁-C₆-alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl-SO₂-O-, the substituents of which are chosen from halogens, pseudohalogens, CH₃ and methoxy; (C₁-C₆-alkyl)SO₂-O-; unsubstituted and at least monosubstituted (C₁-C₆-alkyl)CO, the substituents of which are chosen from F, di(C₁-C₃-alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C₁-C₃-alkyl, halogens and methoxy;

A is chosen from CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is chosen from CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

R⁵ is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH₂; unsubstituted and at least

monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are chosen from F, OH, C₁-C₃-alkoxy, aryloxy, (C₁-C₃-alkyl)mercapto, NH₂, (C₁-C₃-alkyl)amino, and di(C₁-C₃-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; aryl-substituted C₁-C₃-alkyl; heteroaryl-substituted C₁-C₃-alkyl; CF₃; NO₂; OH; phenoxy; benzvloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino; benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶SO₂NH-; R²⁷SO₂N(C₁-C₅-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is chosen from:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, and di(C₁-C₃-alkyl)amino; aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, di(C₁-C₃-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of

the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₈-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;


aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2;

wherein the physiologically active amount of the compound according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof stimulates the expression of endothelial NO-synthase in the mammal.

24. (Previously Presented) A method of treating a mammal suffering from a cardiovascular disease, which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I), in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R^1 and R^4 are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and C_2 - C_{10} -alkynyl, the substituents of which are chosen from F, OH, C_1 - C_8 -alkoxy, $(C_1$ - C_8 -alkyl)mercapto, CN, $COOR^6$, $CONR^7R^8$, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; R^9CO ; $CONR^{10}R^{11}$, $COOR^{12}$, CF_3 ; halogens; pseudohalogens; $NR^{13}R^{14}$, OR^{15} ; $S(O)_mR^{16}$; $SO_2NR^{17}R^{18}$; and NO_2 ;

R^2 and R^3 are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C_1 - C_{10} -alkoxy; phenoxy; $S(O)_mR^{19}$; CF_3 ; CN; NO_2 ; $(C_1$ - C_{10} -alkyl)amino; $di(C_1$ - C_{10} -alkyl)amino; $(C_1$ - C_6 -alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl- SO_2 -O-, the substituents of which are chosen from halogens, pseudohalogens, CH_3 and methoxy; $(C_1$ - C_6 -alkyl) SO_2 -O-; unsubstituted and at least monosubstituted $(C_1$ - C_6 -alkyl)CO, the substituents of which are chosen from F, $di(C_1$ - C_3 -alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of which can be substituted by one or more substituents chosen from C_1 - C_3 -alkyl, halogens and methoxy;

A is chosen from CH_2 , CHOH and $\text{CH}-(\text{C}_1-\text{C}_3\text{-alkyl})$;

B is chosen from CH_2 and $\text{CH}-(\text{C}_1-\text{C}_3\text{-alkyl})$;

C independently has the same meaning as B;

R^5 is a group Ar or a group Heter both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH_2 ; unsubstituted and at least monosubstituted $\text{C}_1-\text{C}_{10}\text{-alkyl}$, $\text{C}_2-\text{C}_{10}\text{-alkenyl}$, $\text{C}_2-\text{C}_{10}\text{-alkynyl}$, $\text{C}_1-\text{C}_{10}\text{-alkoxy}$, $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{amino}$, and $\text{di}(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{amino}$, the substituents of which are chosen from F, OH, $\text{C}_1-\text{C}_8\text{-alkoxy}$, aryloxy , $(\text{C}_1-\text{C}_8\text{-alkyl})\text{mercapto}$, NH_2 , $(\text{C}_1-\text{C}_8\text{-alkyl})\text{amino}$, and $\text{di}(\text{C}_1-\text{C}_8\text{-alkyl})\text{amino}$; $\text{C}_3-\text{C}_5\text{-alkandiyl}$; phenyl ; heteroaryl ; $\text{aryl-substituted C}_1-\text{C}_4\text{-alkyl}$; $\text{heteroaryl-substituted C}_1-\text{C}_4\text{-alkyl}$; CF_3 ; NO_2 ; OH; phenoxy ; benzyloxy ; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{COO}$; $\text{S}(\text{O})_m\text{R}^{20}$; SH; phenylamino ; benzylamino ; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CONH-}$; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; phenyl-CONH- ; $\text{phenyl-CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; heteroaryl-CONH- ; $\text{heteroaryl-CON}(\text{C}_1-\text{C}_4\text{-alkyl})\text{-}$; $(\text{C}_1-\text{C}_{10}\text{-alkyl})\text{-CO}$; phenyl-CO ; heteroaryl-CO ; $\text{CF}_3\text{-CO}$; $\text{-OCH}_2\text{O-}$; $\text{-OCF}_2\text{O-}$; $\text{-OCH}_2\text{CH}_2\text{O-}$; $\text{-CH}_2\text{CH}_2\text{O-}$; COOR^{21} ; $\text{CONR}^{22}\text{R}^{23}$; $\text{CNH}(\text{NH}_2)$; $\text{SO}_2\text{NR}^{24}\text{R}^{25}$; $\text{R}^{26}\text{SO}_2\text{NH-}$; $\text{R}^{27}\text{SO}_2\text{N}(\text{C}_1-\text{C}_6\text{-alkyl})\text{-}$; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, $\text{C}_1-\text{C}_3\text{-alkyl}$, $\text{C}_1-\text{C}_3\text{-alkoxy}$, OH, oxo and CF_3 , and wherein said heterocycles can optionally be condensed to said group Ar or said group Heter; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Heter, can be substituted by one or more substituents chosen from halogens, pseudohalogens, $\text{C}_1-\text{C}_3\text{-alkyl}$, OH, $\text{C}_1-\text{C}_3\text{-alkoxy}$, and CF_3 ;

R^6 is chosen from:

H; $\text{C}_1-\text{C}_{10}\text{-alkyl}$, which can be substituted by one or more substituents chosen from F, $\text{C}_1-\text{C}_8\text{-alkoxy}$, and $\text{di}(\text{C}_1-\text{C}_8\text{-alkyl})\text{amino}$; $\text{aryl}-(\text{C}_1-\text{C}_4\text{-alkyl})$ and $\text{heteroaryl}-(\text{C}_1-\text{C}_4\text{-alkyl})$, which can be

substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₃-alkoxy, di(C₁-C₈-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₃-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2;

wherein the physiologically active amount of the compound according to the general formula (I) in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof stimulates the expression of endothelial NO-synthase in the mammal.

25. (Previously Presented) The method according to claim 24, wherein the compound of the general formula (I) is chosen from compounds of the general formula (I), wherein
- R^1 is chosen from: H; C_1 - C_4 -alkyl; C_1 - C_4 -alkoxy; CF_3 ; halogens; pseudohalogens; (C_1 - C_4 -alkyl)- $S(O)_m$ -; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 , and wherein heteroaryl is chosen from 5- and 6-membered heterocycles containing one or more heteroatoms chosen from N, O, and S;
- R^2 and R^3 are independently from each other chosen from: H; halogens; pseudohalogens; and C_1 - C_3 -alkyl;
- R^4 independently has the same meaning as R^1 ;
- A is chosen from CH_2 and $CHOH$;
- B and C are independently from each other chosen from CH_2 and $CH-CH_3$;
- R^5 is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; CN; NH_2 ; unsubstituted and at least monosubstituted C_1 - C_8 -alkyl, C_2 - C_8 -alkenyl, C_2 - C_8 -alkynyl, C_1 - C_8 -alkoxy, (C_1 - C_8 -alkyl)amino, and di(C_1 - C_8 -alkyl)amino, the substituents of which are chosen from F, C_1 - C_6 -alkoxy, phenoxy, (C_1 - C_6 -alkyl)mercapto, NH_2 , (C_1 - C_6 -alkyl)amino, and di(C_1 - C_6 -alkyl)amino; C_3 - C_3 -alkandiyl; phenyl; heteroaryl; phenyl-substituted C_1 - C_2 -alkyl; heteroaryl-substituted C_1 - C_2 -alkyl; CF_3 ; OH; phenoxy; benzyloxy; (C_1 - C_6 -alkyl)COO; $S(O)_m$ (C_1 - C_6 -alkyl); $S(O)_m$ -phenyl; $S(O)_m$ -heteroaryl; SH; phenylamino; benzylamino; (C_1 - C_6 -alkyl)-CONH-; (C_1 - C_6 -alkyl)-CON(C_1 - C_4 -alkyl)-; phenyl-CONH-; phenyl-CON(C_1 - C_4 -alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C_1 - C_4 -alkyl)-;

(C₁-C₆-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COO(C₁-C₆-alkyl); -CONH₂; -CONH(C₁-C₆-alkyl); -CON(di(C₁-C₆-alkyl)); CNH(NH₂); -SO₂NH₂; -SO₂NH(C₁-C₆-alkyl); -SO₂NH(phenyl); -SO₂N(di(C₁-C₆-alkyl)); (C₁-C₆-alkyl)SO₂NH-; (C₁-C₆-alkyl)SO₂N(C₁-C₆-alkyl)-; phenyl-SO₂NH-; phenyl-SO₂N(C₁-C₆-alkyl)-; heteroaryl-SO₂NH-; heteroaryl-SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Heter; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Heter, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃; heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S; the group Heter is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S; the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and m is 0 or 2.

26. (Previously Presented) The method according to claim 24, wherein the compound according to the general formula (I) is chosen from the compounds of the general formula (I), wherein
- R¹ is H, halogen, or C₁-C₄-alkyl;
- R² and R³ are each H;
- R⁴ independently has the same meaning as R¹;
- A is CH₂;

R^5 is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; CN; NH_2 ; unsubstituted and at least monosubstituted C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_3 -alkoxy, $(C_1$ - C_4 -alkyl)amino, and $di(C_1$ - C_4 -alkyl)amino, the substituents of which are chosen from F, C_1 - C_3 -alkoxy, $(C_1$ - C_3 -alkyl)mercapto, and NH_2 ; C_3 - C_3 -alkandiyl; phenyl; heteroaryl; phenyl-substituted C_1 - C_2 -alkyl; heteroaryl-substituted C_1 - C_2 -alkyl; CF_3 ; OH; $(C_1$ - C_4 -alkyl)COO; $S(O)_m(C_1$ - C_4 -alkyl); $(C_1$ - C_4 -alkyl)-CONH-; $(C_1$ - C_4 -alkyl)-CON(C_1 - C_4 -alkyl)-; $(C_1$ - C_4 -alkyl)-CO; phenyl-CO; heteroaryl-CO; CF_3 -CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COO(C_1 - C_6 -alkyl); -CONH₂; -CONH(C_1 - C_4 -alkyl); -CON($di(C_1$ - C_4 -alkyl)); CNH(NH_2); -SO₂NH₂; -SO₂NH(C_1 - C_4 -alkyl); -SO₂NH(phenyl); -SO₂N($di(C_1$ - C_4 -alkyl)); $(C_1$ - C_4 -alkyl)SO₂NH-; $(C_1$ - C_4 -alkyl)SO₂N(C_1 - C_4 -alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy, OH, oxo and CF_3 , and wherein said heterocycles can optionally be condensed to said phenyl or said group Hetar; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said phenyl or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, OH, C_1 - C_3 -alkoxy, and CF_3 ; heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms chosen from N, O, and S; the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one, two or three heteroatoms chosen from N, O, and S; and m is 0 or 2.

27. (Previously Presented) The method according to claim 24, wherein the compound according to the general formula (I) is chosen from the compounds of the general formula (I) wherein

R¹ is H, halogen, or C₁-C₄-alkyl;

R² and R³ are each H;

R⁴ independently has the same meaning as R¹;

A and B are each CH₂;

C is CH₂ or CH-CH₃;


R⁵ is phenyl or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: F; Cl; Br; C₁-C₃-alkyl; C₁-C₃-alkoxymethyl; 2-amino-3,3,3-trifluoropropyl-; CF₃; C₃-C₅-alkandiyl; phenyl; heteroaryl; benzyl; heteroaryl-methyl; OH; C₁-C₃-alkoxy; phenoxy; trifluoromethoxy; 2,2,2-trifluoroethoxy; (C₁-C₄-alkyl)COO; (C₁-C₃-alkyl)mercapto; phenylmercapto; (C₁-C₃-alkyl)sulfonyl; phenylsulfonyl; NH₂; (C₁-C₄-alkyl)amino; di(C₁-C₄-alkyl)amino; (C₁-C₃-alkyl)-CONH-; (C₁-C₃-alkyl)-SO₂NH-; (C₁-C₃-alkyl)-CO; phenyl-CO; -OCH₂O-; -OCF₂O-; -CH₂CH₂O-; COO(C₁-C₄-alkyl); -CONH₂; -CONH(C₁-C₄-alkyl); -CON(di(C₁-C₄-alkyl)); CN; -SO₂NH₂; -SO₂NH(C₁-C₄-alkyl); -SO₂N(di(C₁-C₄-alkyl)); pyrrolidinyl; piperidinyl; morpholinyl; and thiomorpholinyl; and wherein all heteroaryl, phenyl, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said phenyl or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃; heteroaryl is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl; the group Hetar is chosen from: furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridazinyl, pyrazinyl, pyridyl, pyrimidinyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolyl, indolyl, benzofuranyl, benzothiophenyl, and indazolyl.

28. (Previously Presented) The method according to claim 24, wherein the compound according to the general formula (I) is chosen from the compounds of the general formula (I) wherein
- R^1 is H, halogen or C_1 - C_4 -alkyl;
- R^2 and R^3 are each H;
- R^4 independently has the same meaning as R^1 ;
- A and B are each CH_2 ;
- C is CH_2 or $CH-CH_3$;
- R^5 is chosen from: 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-(C_1 - C_3 -alkoxy)-phenyl, 4-trifluoromethoxyphenyl, 2-bromo-4-fluorophenyl, 2-chloro-4-fluorophenyl, 3,4-dimethylphenyl, 2,4-dimethylphenyl, 4-chloro-2-methylphenyl, 2-hydroxy-4-methylphenyl, 2-hydroxy-4-ethoxyphenyl, 2-methoxy-4-methylphenyl, 4-phenoxyphenyl, 3-fluoro-4-methylphenyl, benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzimidazole-5-yl, 2-methyl-3H-benzimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl, 2-methyl-thiazole-5-yl, 2-

morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3-dimethylamino-4-methyl-phenyl, 3-dimethylamino-phenyl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methanesulfonylamino-2-methyl-phenyl, 3-methanesulfonylamino-phenyl, 3-methyl-isoxazole-4-yl, 3-morpholin-4-yl-phenyl, 3-piperidin-1-yl-phenyl, 3-pyrrolidin-1-yl-phenyl, 4-(2,2,2-trifluoro-ethoxy)-phenyl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethyl sulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-chloro-3-methanesulfonylamino-phenyl, 4-chloro-3-sulfamoyl-phenyl, 4-methyl-3-methylamino-phenyl, 4-methyl-thiazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 5-thiophen-2-yl-pyrid-3-yl, 2-methyl-4-trifluoromethyl-thiazol-5-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methanesulfonyl-2-methyl-phenyl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

29. (Previously Presented) The method according to claim 24, wherein the mammal is a human.
30. (Previously Presented) A method of treating a mammal suffering from a disease chosen from stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the

liver, osteoporosis, diseases with symptoms of restricted memory performance and/or a restricted ability to learn, which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I), in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein R^1 is H, halogen or C_1 - C_4 -alkyl;

R^2 and R^3 are each H;

R^4 independently has the same meaning as R^1 ;

A and B are each CH_2 ;


C is CH_2 or $CH-CH_3$;

R^5 is chosen from: benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzoimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzoimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-

pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, 2-methyl-3H-benzoimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl, 2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methyl-isoxazole-4-yl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethylsulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-methyl-thiazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 5-thiophen-2-yl-pyrid-3-yl, 2-methyl-4-trifluoromethyl-thiazol-5-yl, 5,6,7,8-tetrahydro-quinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

31. (Previously Presented) The method according to claim 30, wherein the hypertension is chosen from essential hypertension, pulmonary hypertension, secondary hypertension, and renovascular hypertension.
32. (Previously Presented) The method according to claim 30, wherein the diabetes complications are chosen from nephropathy and retinopathy.
33. (Previously Presented) The method according to claim 30, which method lowers cardiovascular risk of postmenopausal women and mammals taking contraceptives.

34. (Previously Presented) The method according to claim 30, wherein the mammal is a human.
35. (Previously Presented) A method of treating a mammal suffering from a cardiovascular disease, which method comprises administering to said mammal a physiologically active amount of a compound according to the general formula (I), in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein R^1 is H, halogen or C_1 - C_4 -alkyl;

R^2 and R^3 are each H;

R^4 independently has the same meaning as R^1 ;

A and B are each CH_2 ;


C is CH_2 or $CH-CH_3$;

R^5 is chosen from: benzo[1,3]dioxol-5-yl, 2,2-difluoro-benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzofuran-5-yl, 1-(4-chloro-phenyl)-5-trifluoromethyl-1H-pyrazole-4-yl, 1-(4-fluoro-phenyl)-3,5-dimethyl-1H-pyrazole-4-yl, 1H-benzotriazole-5-yl, 1H-indole-4-yl, 1H-indole-6-yl, 1-isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-yl, 1-methyl-3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-yl, 1-phenyl-5-trifluoromethyl-1H-pyrazole-4-yl, 2-(2-hydroxy-pyridin-4-yl)-1H-benzoimidazole-5-yl, 2-(4-cyano-phenyl)-1H-benzoimidazole-5-yl, 2,4-dimethyl-oxazole-5-yl, 2,4-dimethyl-pyrimidine-5-yl, 2,4-dimethyl-thiazole-5-yl, 2,5-dimethyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-phenyl-1H-pyrrole-3-yl, 2,5-dimethyl-1-pyridin-4-ylmethyl-1H-pyrrolyl, 2,5-dimethyl-2H-pyrazole-3-yl, 2,6-dichloro-pyrid-3-yl, 2,6-dimethoxy-pyrid-3-yl, 2,6-dimethyl-pyrid-3-yl, 2-amino-4,6-dimethyl-pyrid-3-yl, 2-amino-6-chloro-pyrid-3-yl, 2-amino-pyrid-3-yl, 2-

chloro-6-methyl-pyrid-3-yl, 2-chloro-pyrid-4-yl, 2-cyclopropyl-4-methyl-thiazole-5-yl, 2-dimethylamino-4-methyl-thiazole-5-yl, 2-dimethylamino-pyrid-4-yl, 2-ethyl-5-methyl-2H-pyrazole-3-yl, 2-hydroxy-6-methyl-pyrid-3-yl, 2-methyl-1H-benzoimidazole-5-yl, 2-methyl-3H-benzoimidazole-5-yl, 2-methyl-pyrid-3-yl, 2-methyl-6-trifluoromethyl-pyrid-3-yl, 2-methyl-thiazole-5-yl, 2-morpholin-4-yl-pyridin-4-yl, 2-morpholin-4-yl-pyrimidine-5-yl, 2-pyrrolidin-1-yl-pyridin-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, 3-amino-5,6-dimethyl-pyrazine-2-yl, 3-amino-5-methyl-pyrazine-2-yl, 3-amino-pyrazine-2-yl, 3H-benzoimidazole-5-yl, 1H-benzoimidazole-5-yl, 3-methyl-isoxazole-4-yl, 4,6-dimethyl-pyrid-3-yl, 4-amino-2-ethylsulfanyl-pyrimidine-5-yl, 4-amino-2-methyl-pyrimidine-5-yl, 4-methyl-thiazole-5-yl, pyridine-2-yl, pyridine-3-yl, pyridine-4-yl, 5-thiophen-2-yl-pyrid-3-yl, 2-methyl-4-trifluoromethyl-thiazol-5-yl, 5,6,7,8-tetrahydroquinoline-3-yl, 5-amino-1-phenyl-1H-pyrazole-4-yl, 5-methyl-1-phenyl-1H-pyrazole-4-yl, 5-methyl-isoxazole-3-yl, 5-methyl-pyrid-3-yl, 5-methyl-pyrazine-2-yl, 6-chloro-pyrid-3-yl, 6-cyano-pyrid-3-yl, 6-dimethylamino-pyrid-3-yl, 6-ethynyl-pyrid-3-yl, 6-methoxymethyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-methyl-2-methylamino-pyrid-3-yl, 6-methylamino-pyrazine-2-yl, 6-methyl-pyrid-3-yl, 6-morpholin-4-yl-pyrid-3-yl, 6-pyrrolidin-1-yl-pyrid-3-yl, imidazo[1,2-a]pyridine-2-yl, 6-trifluoromethyl-pyrid-3-yl, and pyrimidine-4-yl.

36. (Previously Presented) The method according to claim 35, wherein the mammal is a human.
37. (Previously Presented) A method of treating a mammal suffering from a disease chosen from stable and unstable angina pectoris, coronary heart disease, acute coronary syndrome, heart failure, myocardial infarction, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, and osteoporosis, which method comprises administering to said mammal a physiologically active

amount of a compound according to the general formula (I), in any of its stereoisomeric forms or a mixture thereof in any ratio or a pharmaceutically acceptable salt thereof



wherein, in the formula (I),

R^1 and R^4 are independently from each other chosen from :

H; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl and C_2 - C_{10} -alkynyl, the substituents of which are chosen from F, OH, C_1 - C_8 -alkoxy, $(C_1$ - C_8 -alkyl)mercapto, CN, $COOR^6$, $CONR^7R^8$, and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy and CF_3 ; R^9CO ; $CONR^{10}R^{11}$; $COOR^{12}$; CF_3 ; halogens; pseudohalogens; $NR^{13}R^{14}$; OR^{15} ; $S(O)_mR^{16}$; $SO_2NR^{17}R^{18}$; and NO_2 ;

R^2 and R^3 are independently from each other chosen from:

H; halogens; pseudohalogens; unsubstituted and at least monosubstituted C_1 - C_{10} -alkyl the substituents of which are chosen from OH, phenyl, and heteroaryl; OH; C_1 - C_{10} -alkoxy; phenoxy; $S(O)_mR^{19}$; CF_3 ; CN; NO_2 ; $(C_1$ - C_{10} -alkyl)amino; di(C_1 - C_{10} -alkyl)amino; $(C_1$ - C_6 -alkyl)-CONH-; unsubstituted and at least monosubstituted phenyl-CONH- and phenyl- SO_2 -O-, the substituents of which are chosen from halogens, pseudohalogens, CH_3 and methoxy; $(C_1$ - C_6 -alkyl) SO_2 -O-; unsubstituted and at least monosubstituted $(C_1$ - C_6 -alkyl)CO, the substituents of which are chosen from F, di(C_1 - C_3 -alkyl)amino, pyrrolidinyl and piperidinyl; and phenyl-CO, the phenyl part of

which can be substituted by one or more substituents chosen from C₁-C₃-alkyl, halogens and methoxy;

A is chosen from CH₂, CHOH and CH-(C₁-C₃-alkyl);

B is chosen from CH₂ and CH-(C₁-C₃-alkyl);

C independently has the same meaning as B;

R⁵ is a group Ar or a group Hetar both of which can be unsubstituted or carry one or more substituents chosen from: halogens; pseudohalogens; NH₂; unsubstituted and at least monosubstituted C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₁-C₁₀-alkoxy, (C₁-C₁₀-alkyl)amino, and di(C₁-C₁₀-alkyl)amino, the substituents of which are chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, NH₂, (C₁-C₈-alkyl)amino, and di(C₁-C₈-alkyl)amino; C₃-C₅-alkandiyl; phenyl; heteroaryl; aryl-substituted C₁-C₄-alkyl; heteroaryl-substituted C₁-C₄-alkyl; CF₃; NO₂; OH; phenoxy; benzyloxy; (C₁-C₁₀-alkyl)COO; S(O)_mR²⁰; SH; phenylamino; benzylamino; (C₁-C₁₀-alkyl)-CONH-; (C₁-C₁₀-alkyl)-CON(C₁-C₄-alkyl)-; phenyl-CONH-; phenyl-CON(C₁-C₄-alkyl)-; heteroaryl-CONH-; heteroaryl-CON(C₁-C₄-alkyl)-; (C₁-C₁₀-alkyl)-CO; phenyl-CO; heteroaryl-CO; CF₃-CO; -OCH₂O-; -OCF₂O-; -OCH₂CH₂O-; -CH₂CH₂O-; COOR²¹; CONR²²R²³; CNH(NH₂); SO₂NR²⁴R²⁵; R²⁶SO₂NH-; R²⁷SO₂N(C₁-C₆-alkyl)-; and saturated and at least monounsaturated aliphatic, mononuclear 5- to 7-membered heterocycles containing 1 to 3 heteroatoms chosen from N, O, and S, which heterocycles can be substituted by one or more substituents chosen from halogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, OH, oxo and CF₃, and wherein said heterocycles can optionally be condensed to said group Ar or said group Hetar; and wherein all aryl, heteroaryl, phenyl, aryl-containing, heteroaryl-containing and phenyl-containing groups, which are optionally present in said substituents of said group Ar or said group Hetar, can be substituted by one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, OH, C₁-C₃-alkoxy, and CF₃;

R⁶ is chosen from:

H; C₁-C₁₀-alkyl, which can be substituted by one or more substituents chosen from F, C₁-C₈-alkoxy, and di(C₁-C₃-alkyl)amino; aryl-(C₁-C₄-alkyl) and heteroaryl-(C₁-C₄-alkyl), which can be substituted by one or more substituents chosen from halogens, C₁-C₄-alkoxy, and di(C₁-C₆-alkyl)amino;

R⁷ is chosen from:

H; C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, C₁-C₈-alkoxy, di(C₁-C₃-alkyl)amino and phenyl; phenyl; indanyl; and heteroaryl; and wherein each of the aforementioned aromatic groups can be unsubstituted or carry one or more substituents chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃;

R⁸ is H or C₁-C₁₀-alkyl;

R⁹ is chosen from: C₁-C₁₀-alkyl which can be unsubstituted or carry one or more substituents chosen from: F, (C₁-C₄)-alkoxy, di(C₁-C₃-alkyl)amino; and unsubstituted and at least monosubstituted phenyl and heteroaryl, the substituents of which are chosen from C₁-C₃-alkyl, C₁-C₃-alkoxy, halogens, pseudohalogens, and CF₃;

R¹⁰ independently has the same meaning as R⁷;

R¹¹ independently has the same meaning as R⁸;

R¹² independently has the same meaning as R⁶;

R¹³ is chosen from: H; C₁-C₆-alkyl; unsubstituted and substituted phenyl, benzyl, heteroaryl, (C₁-C₆-alkyl)-CO, phenyl-CO, and heteroaryl-CO, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁴ independently has the same meaning as R¹³;

R¹⁵ is chosen from: H; C₁-C₁₀-alkyl; (C₁-C₃-alkoxy)-C₁-C₃-alkyl; and substituted and unsubstituted benzyl, phenyl and heteroaryl, the substituents of which are chosen from halogens,

pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy, and CF₃, and wherein one or more of these substituents can be present;

R¹⁶ is chosen from: C₁-C₁₀-alkyl which can be substituted by one or more substituents chosen from F, OH, C₁-C₈-alkoxy, aryloxy, (C₁-C₈-alkyl)mercapto, (C₁-C₈-alkyl)amino and di(C₁-C₈-alkyl)amino; CF₃; and substituted and unsubstituted phenyl and heteroaryl, the substituents of which are chosen from halogens, pseudohalogens, C₁-C₃-alkyl, C₁-C₃-alkoxy and CF₃, and wherein one or more of these substituents can be present;

R¹⁷ independently has the same meaning as R⁷;

R¹⁸ independently has the same meaning as R⁸;

R¹⁹ independently has the same meaning as R¹⁶;

R²⁰ independently has the same meaning as R¹⁶;

R²¹ independently has the same meaning as R⁶;

R²² independently has the same meaning as R⁷;

R²³ independently has the same meaning as R⁸;

R²⁴ independently has the same meaning as R⁷;

R²⁵ independently has the same meaning as R⁸;

R²⁶ independently has the same meaning as R¹⁶;

R²⁷ independently has the same meaning as R¹⁶;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

the group Hetar is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O, and S;

aryl is phenyl, naphth-1-yl or naphth-2-yl;

the group Ar is phenyl, naphth-1-yl or naphth-2-yl; and

m is 0, 1 or 2.

FEB. 11. 2005 3:03PM

AVENTIS US PAT DEPT

NO. 2190 P. 56

PAGE 56/56 * RCVD AT 2/11/2005 2:28:45 PM [Eastern Standard Time] * SVR:USPTO-EFAX-1/0 * DNIS:8729306 * CSID:908 231 2626 * DURATION (mm-ss):34-00

Page left blank